Register Now
Course Information

You Don’t Want to Miss This Activity

The San Antonio Breast Cancer Symposium® (SABCS®) is the premiere breast cancer conference in the U.S. and the world for breast disease. The Symposium aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with a special interest in breast cancer. The SABCS® is celebrating its 47th anniversary in 2024.

This Official Best of SABCS®, sponsored by Cleveland Clinic Florida, reviews the highlights originally presented at SABCS® 2024 in a one-day program. This symposium will provide oncologists and other healthcare professionals with a wide range of information related to new and well-established topics in breast cancer, including, but not limited to: 

  • State-of-the-art information on Breast Cancer
  • Surgery and Local Management
  • Hormone Receptor-Positive Breast Cancer
  • Advances in HER2 Positive Breast Cancer
  • Triple-negative and BRCA-related Breast Cancer
  • Updates on Radiation and Local Therapies
  • Breast Cancer Prevention, Quality of Life and Survivorship Care
  • Addressing Toxicities of Novel Therapy
  • Biomarkers and Molecular Profiling in Breast Cancer
  • Late-breaking Abstracts and Research in the Pipeline

This important educational activity also provides a forum for interaction between individuals involved with all aspects of breast cancer care and the opportunity to converse with colleagues and key opinion leaders.

Our target audience includes physicians and other healthcare professionals, who are involved with the treatment of breast cancer, including those in the fields of Oncology, Internal Medicine & Subspecialties, Radiology, Endocrinology, Women’s Healthcare and Pharmacology.

This activity is multi-funded, fully complies with ACCME Standards for Integrity and Independence in Accredited Continuing Education, is developed independently and is without influence from any commercial interests.


  • Discuss the research and advances in breast cancer with colleagues and key opinion leaders
  • Integrate into clinical practice various evidence-based advances to management of persons with breast cancer as it relates to imaging, surgery and local and systemic therapies surrounding HER2+, triple negative breast cancer, hormonal therapy, locoregional advances, molecular predictions models and survivorship
  • Report the most current information on breast cancer research presented at the meeting in San Antonio in December